Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly

By Pharmaceutical Processing | May 26, 2011

 

Amylin Pharmaceuticals, Inc. today announced that the United States
District Court for the Southern District of California issued a temporary
restraining order (TRO) against Eli Lilly and Company relating to its
litigation with respect to the Amylin / Lilly diabetes collaboration agreement.

The U.S. District Court restrained Lilly from proceeding
with its plans to use the same sales force to sell both exenatide and Boehringer
Ingelheim GmbH’s competitive linagliptin. The court also enjoined Lilly from
disclosing any confidential information about exenatide to any of its sales
representatives or employees participating in the marketing, promotion or sale
of linagliptin.

The complete order is being filed today on Amylin’s Current
Report on Form 8-K with the Securities and Exchange Commission.

In 2002, Amylin entered an alliance with Lilly for the
global development and commercialization of exenatide, a medicine indicated as
a first line treatment for type 2 diabetes that is currently marketed as BYETTA
(exenatide) injection. Exenatide is also the active ingredient in BYDUREONT
(exenatide extended-release for injectable suspension), a once-weekly version
currently under review by the FDA.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE